Ebola virus genome provides clues to repeated disease 'flare-ups' in Western Africa

02-May-2016 - Ebola virus samples taken from patients in Liberia in June 2015 are strikingly similar in their genetic makeup to other Ebola virus sequences from Western Africa. The study sheds light on several aspects of the "flare-ups" that have occurred in Liberia since the country was initially declared ...

Human antibodies produced in DNA-vaccinated cows protect in lethal models of hantavirus

02-Dec-2014 - Scientists investigating the potentially deadly hantavirus have used a novel approach to developing protective antibodies against it. Their work, published in Science Translational Medicine, provides proof of concept for producing antibodies against a broad range of human pathogens. Hantaviruses ...

USAMRIID research sheds light on how deadly lassa virus infects cells

02-Jul-2014 - Scientists have discovered that the Lassa virus, which is endemic to West Africa, uses an unexpected two-step process to enter cells. The results, published in Science, suggest that the mechanism by which Lassa virus causes infection is more complicated than previously known. An international ...

Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses

23-Aug-2010 - New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure — suggesting the approach holds promise for treating accidental ...

Single host gene may hold key to treating both ebola and anthrax infections

24-Aug-2009 - Research published by Army scientists indicates that a minor reduction in levels of one particular gene, known as CD45, can provide protection against two divergent microbes: the virus that causes Ebola hemorrhagic fever and the bacterium that causes anthrax. Taken together, the results suggest a ...

Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic Effect in New Primate Model

Pilot Study Demonstrates 50% Survival in Valortim-Treated Animals

03-Apr-2007 - Medarex, Inc. and PharmAthene, Inc. announced that Valortim(TM), a fully human monoclonal antibody product candidate being developed for the prevention and treatment of anthrax infection, has been shown to have a therapeutic effect in a new primate model of established inhalation anthrax ...

Elusys and U.S. Army extend biodefense collaboration

19-Dec-2006 - Elusys Therapeutics, Inc. announced that it has extended its Cooperative Research and Development Agreement (CRDA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). Under the agreement, both parties will continue to perform collaborative research to develop ...

Alnylam To Collaborate with United States Army on RNAi Therapeutics for Biodefense Threats

18-Apr-2006 - Alnylam Pharmaceuticals, Inc. announced the signing of a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). Under the agreement, Alnylam will collaborate with USAMRIID to discover RNAi therapeutics ...

Viragen Reports on Multiferon Anti-Viral Studies with U.S. Army Researchers

09-Feb-2006 - Viragen, Inc. and its majority-owned subsidiary, Viragen International, Inc., reported on the progression of anti-viral studies using Multiferon® (multi-subtype, natural human alpha interferon) being conducted by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). These ...

Corgenix to develop diagnostic tests for bioterrorism agents under multi-million dollar NIH contract

Company expands presence into BioDefense

14-Nov-2005 - Corgenix Medical Corporation, in partnership with Tulane University, the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and two corporate partners, will develop and manufacture improved diagnostic tests for viral hemorrhagic fevers under a $3.8 million grant awarded by the ...